Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04833465 · ClinicalTrials.gov registry record

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

A clinical trial of Systemic Lupus Erythematosus and Fibromyalgia, sponsored by Children's National Research Institute.

Recruiting
Registry status
90
Enrollment target
1
Study location

NCT04833465 is a study of Systemic Lupus Erythematosus and Fibromyalgia that is actively recruiting participants, run by Children's National Research Institute. The registered enrollment target is 90 participants, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04833465, a study of Systemic Lupus Erythematosus and Fibromyalgia, is actively recruiting participants, sponsored by Children's National Research Institute.

RECRUITING
Registry status
90 participants
Enrollment target
1
Study location

Study Summary

The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations. This would enable objective assessment of pain and treatment in these populations and enable a much more precise approach to treatment. Such an endpoint stands to significantly improve outcomes in these patients by eliminating the need for a trial-and-error approach to treatment. This is a single site observational study that aims to collect initial pilot data in three distinct patient groups. As this is observational, there is no randomization or blinding in the study. Patients will be followed for a period of one year after enrollment. Baseline measurements will be taken at the time of enrollment, and at each subsequent standard of care clinic visit as feasible, for a period of one year. As this is an observational study, there will be no change to the treatment for any patient due to research activities. The primary objective of this study is the characterization of the nociceptive index in three pediatric rheumatology populations. The secondary objective is the characterization of the nociceptive index in these populations in response to standard of care interventions. This is necessary to demonstrate the ability of this approach to serve as an endpoint of treatment effect.

Interventions

  • OTHER No Intervention

Study Locations (1)

District of Columbia

  • Children's National Health System - Washington D.C.

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2021-07-16
Est. Completion 2025-12-01

What the Registry Record Tells You About NCT04833465

The ClinicalTrials.gov registry entry for NCT04833465 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 379-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (76% lower). The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.

NCT04833465 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT04833465 about?

NCT04833465 is a clinical study titled "Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions". The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations. This would enable objective assessment of pain and treatment in these populations and enable a much more precise approach to treatment. Such an end...

What is the current status of trial NCT04833465?

This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2021-07-16. Estimated completion is 2025-12-01.

What conditions does trial NCT04833465 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Fibromyalgia, Juvenile Idiopathic Arthritis.

What interventions are being tested in trial NCT04833465?

The interventions under investigation include: No Intervention (OTHER).

Who is sponsoring clinical trial NCT04833465?

This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04833465 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.